Viking Closes $548M Concurrent Offering After Full Over-Allotment Exercise
VKTX sits 34% above its 52-week low of $24.88 on elevated volume (2.4× avg).
Summary
Viking Therapeutics closed its $548 million concurrent equity and convertible notes offering after underwriters fully exercised both over-allotment options, adding approximately $547.8 million in net proceeds for its obesity and metabolic pipeline.
Key Events · Financing and Capital Events · VKTX
-
Concurrent Offering Closed
Viking closed its upsized concurrent offering on September 25, 2026, with underwriters fully exercising both over-allotment options.
-
Equity Tranche Expanded
The common stock offering grew to 9,035,714 shares at $35.00 per share, generating approximately $297.0 million in net proceeds after discounts and expenses.
-
Convertible Notes Tranche Expanded
The 2.00% convertible senior notes due 2032 tranche increased to $258.75 million principal amount, adding approximately $250.8 million in net proceeds at a $50.75 conversion price.
-
Use of Proceeds
Combined net proceeds of approximately $547.8 million fund continued clinical development of VK2735 and VK3019, plus general R&D and working capital.
Analysis · VKTX · Life Sciences
Viking Therapeutics closed its upsized concurrent offering on September 25, 2026, with underwriters exercising in full their over-allotment options for both tranches. The equity offering grew to 9,035,714 shares at $35.00, generating approximately $297.0 million in net proceeds, while the convertible notes tranche expanded to $258.75 million principal amount, adding approximately $250.8 million in net proceeds. Combined net proceeds of roughly $547.8 million fund the VK2735 and VK3019 clinical programs. The full exercise of both options signals strong institutional demand, though the equity tranche priced at a discount to the $41.65 last reported sale price on September 23, 2026.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VKTX was trading at $33.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $24.88 to $43.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.